W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies
X

Home » Results:(Strona 3)

Position of the Transparency Council – Kyprolis (carfilzomib)

22 February, 2023
więcej...

Opinion of the Transparency Council – abiraterone acetate

22 February, 2023
więcej...

Opinion of the Transparency Council – amendments to the drug programme B.56

22 February, 2023
więcej...

Opinion of the Transparency Council – trastuzumab

22 February, 2023
więcej...

Opinion of the Transparency Council – amendments to the drug programme B.47

22 February, 2023
więcej...

Opinion of the Transparency Council – stiripentol

22 February, 2023
więcej...

Opinion of the Transparency Council – amendments to the drug programme B.90

22 February, 2023
więcej...

Position of the Transparency Council – Apexxnar

22 February, 2023
więcej...

Position of the Transparency Councii – Lorviqua (lorlatinib)

22 February, 2023
więcej...

Opinion of the Transparency Council – venlafaxine

22 February, 2023
więcej...

Opinion of the Transparency Council – metformin

22 February, 2023
więcej...

Opinion of the Transparency Council – chloroquine

22 February, 2023
więcej...

Position of the Transparency Council – Keytruda (pembrolizumab) eTNBC

22 February, 2023
więcej...

Position of the Transparency Council – Keytruda (pembrolizumab) mTNBC

22 February, 2023
więcej...

Position of the Transparency Council – Beovu (brolucizumab)

22 February, 2023
więcej...

Position of the Transparency Councii – Ofev (nintedanib)

22 February, 2023
więcej...

Position of the Transparency Council – Brukinsa (zanubrutinib)

22 February, 2023
więcej...

Opinion of the Transparency Council – health policy pof the City of Opole in the field of early detection of hearing and vision impairment in children

22 February, 2023
więcej...

Opinion of the Transparency Council – M-TYPER

22 February, 2023
więcej...

Position of the Transparency Council – Verzenios (abemaciclib)

22 February, 2023
więcej...

Position of the Transparency Council – Libtayo (cemiplimab)

22 February, 2023
więcej...

Position of the Transparency Council – Reducto spezial (potassium dihydrogen phosphate, sodium monohydrogen phosphate)

22 February, 2023
więcej...

Position of the Transparency Council – Fostex Nexthaler (beclometasone dipropionate) anhydrous + formoterol fumarate dihydrate

22 February, 2023
więcej...

The Transparency Council meeting 9/2023 on 27 February 2023

21 February, 2023
więcej...
Home page
Telefon
Email